サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1390889

速効型インスリン市場：世界の産業動向、シェア、市場規模、成長、機会、2023-2028年予測

Rapid Acting Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 141 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.46円
速効型インスリン市場：世界の産業動向、シェア、市場規模、成長、機会、2023-2028年予測
出版日: 2023年11月24日
発行: IMARC
ページ情報: 英文 141 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

速効型インスリンの世界市場規模は2022年に74億米ドルに達しました。今後、IMARC Groupは、市場が2028年までに97億米ドルに達し、2022～2028年の成長率（CAGR）は4.61%になると予測しています。患者の重症化リスクと死亡率の増加、大衆の個別化医療への関心の高まり、研究開発（R&D）活動への投資の増加は、市場を推進する主な要因の一部です。

速効型インスリンは糖尿病治療に用いられるインスリンの一種で、特に食後の血糖値上昇を管理するために用いられます。食後の自然なインスリン反応を模倣するように設計されており、注射後15分以内に作用が発現します。この迅速な作用は、グルコースの体内代謝を調節する働きがあるため、血糖値を効果的にコントロールするのに役立ちます。速効型インスリンは投与後1～2時間で効果がピークに達するため、この重要な時間帯に高血糖を効率的に下げることができます。速効型インスリン製剤は、糖尿病患者に対して、食事の摂取量に相関した注射のタイミングをとることを可能にし、より個別化された治療アプローチを提供します。糖尿病管理を強化し、患者のQOLを向上させ、血糖値のコントロール不能に伴う合併症のリスクを軽減します。

速効型インスリン製剤は、糖尿病治療に使用されるインスリン製剤の一種で、特に食後の血糖値上昇を管理するために使用されます。食後の自然なインスリン反応を模倣するように設計されており、注射後15分以内に作用が発現します。この迅速な作用は、グルコースの体内代謝を調節する働きがあるため、血糖値を効果的にコントロールするのに役立ちます。速効型インスリンは投与後1～2時間で効果がピークに達するため、この重要な時間帯に高血糖を効率的に下げることができます。速効型インスリン製剤は、糖尿病患者に対して、食事の摂取量に相関した注射のタイミングをとることを可能にし、より個別化された治療アプローチを提供します。糖尿病管理を強化し、患者の生活の質を向上させ、血糖値のコントロール不能に伴う合併症のリスクを低減します。

速効型インスリン市場の動向と促進要因：

大衆における糖尿病の有病率の増加

糖尿病の罹患率は世界的に憂慮すべき速度でエスカレートしています。座りがちなライフスタイル、不健康な食習慣、肥満は、糖尿病の罹患率上昇の主な要因の一部です。糖尿病と診断される人が増えるにつれて、効果的で即効性のあるインスリンの需要は増加の一途をたどっています。速効型インスリンは、食後の血糖値上昇を管理する上で重要な役割を果たし、患者にグルコースレベルをより迅速かつ効率的にコントロールする方法を提供します。ヘルスケア担当者は、食後すぐに必要なインスリンに対応し、高血糖とそれに伴う合併症のリスクを軽減するために、速効型インスリンを処方することが増えています。糖尿病人口の拡大に伴い、製薬会社は速効型インスリン製剤を改良するための研究開発にさらに投資し、その有効性と患者にとっての利便性を高めています。

絶え間ない技術の進歩

医療技術の革新は、インスリン送達システムに革命をもたらし、より使いやすく、より正確になりました。インスリンペン、インスリンポンプ、連続グルコースモニタリング（CGM）デバイスは、糖尿病患者の間でますます普及しており、インスリンの容易な投与と正確な投与を容易にしています。速効型インスリン製剤は、これらの最新の送達システムで最適に機能するように設計されており、その需要はさらに高まっています。インスリン・ペンは、目立たず便利なインスリン投与を提供し、インスリン・ポンプは、個々のニーズに基づいた持続的で個別化されたインスリン注入を提供します。これらの技術革新により、血糖コントロールが改善され、低血糖エピソードのリスクが減少し、患者の全体的な生活の質が向上しました。その結果、速効型インスリンとこれらの先進デバイスとの適合性が、市場成長の大きな原動力となっています。

意識の高まりとヘルスケアインフラ

糖尿病とその管理に関する意識の高まりは、ヘルスケアインフラの拡大と相まって、速効型インスリンの需要に大きく寄与しています。糖尿病啓発キャンペーン、教育イニシアティブ、スクリーニング・プログラムは、患者の早期診断とタイムリーな介入につながり、適切な治療を求める患者数を増加させています。医師やヘルスケア専門家は、患者が食後のグルコースコントロールを改善し、高血糖エピソードや長期合併症を予防できるよう、速効型インスリンを処方するようになってきています。さらに、政府やヘルスケア機関は糖尿病管理プログラムに投資し、速効型インスリンを含む必須薬剤へのアクセスを改善しています。認知度の向上、ヘルスケア施設の充実、糖尿病治療の低価格化などが相まって、速効型インスリン市場の拡大に有利な環境が整いつつあります。

本レポートで扱う主な質問

  • 世界の速効型インスリン製剤市場はこれまでどのように推移してきたか？
  • 速効型インスリンの世界市場における促進要因、市場抑制要因、機会は何か？
  • 各駆動要因、抑制要因、機会が世界の速効型インスリン市場に与える影響は？
  • 主要な地域市場は？
  • 最も魅力的な速効型インスリン市場を代表する国は？
  • 製品別の市場内訳は？
  • 速効型インスリン市場で最も魅力的な製品は？
  • 適応症別の市場内訳は？
  • 速効型インスリン市場で最も魅力的な適応症は？
  • 販売チャネル別の市場内訳は？
  • 速効型インスリン市場で最も魅力的な流通チャネルは？
  • 世界の速効型インスリン市場の競争構造は？
  • 速効型インスリンの世界市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 速効型インスリンの世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品別

  • リスプロインスリン
    • 市場動向
    • 市場予測
  • アスパルトインスリン
    • 市場動向
    • 市場予測
  • グルリシンインスリン
    • 市場動向
    • 市場予測

第7章 市場内訳：適応症別

  • 1型糖尿病
    • 市場動向
    • 市場予測
  • 2型糖尿病
    • 市場動向
    • 市場予測

第8章 市場内訳：流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • ドラッグストア・小売薬局
    • 市場動向
    • 市場予測
  • オンラインストア
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Adocia
    • Biocon Limited
    • Eli Lilly and Company
    • Gan & Lee Pharmaceuticals Co. Ltd.
    • Geropharm
    • MannKind Corporation
    • Merck & Co. Inc.
    • Novo Nordisk A/S
    • Sanofi S.A.
    • Wockhardt Ltd.
図表

List of Figures

  • Figure 1: Global: Rapid Acting Insulin Market: Major Drivers and Challenges
  • Figure 2: Global: Rapid Acting Insulin Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Rapid Acting Insulin Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Rapid Acting Insulin Market: Breakup by Product (in %), 2022
  • Figure 5: Global: Rapid Acting Insulin Market: Breakup by Indication (in %), 2022
  • Figure 6: Global: Rapid Acting Insulin Market: Breakup by Distribution Channel (in %), 2022
  • Figure 7: Global: Rapid Acting Insulin Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Rapid Acting Insulin (Lispro Insulin) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Rapid Acting Insulin (Lispro Insulin) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Rapid Acting Insulin (Aspart Insulin) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Rapid Acting Insulin (Aspart Insulin) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Rapid Acting Insulin (Glulisine Insulin) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Rapid Acting Insulin (Glulisine Insulin) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Rapid Acting Insulin (Type 1 Diabetes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Rapid Acting Insulin (Type 1 Diabetes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Rapid Acting Insulin (Type 2 Diabetes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Rapid Acting Insulin (Type 2 Diabetes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Rapid Acting Insulin (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Rapid Acting Insulin (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Rapid Acting Insulin (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Rapid Acting Insulin (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Rapid Acting Insulin (Online Stores) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Rapid Acting Insulin (Online Stores) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: North America: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: North America: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: United States: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: United States: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Canada: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Canada: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Asia-Pacific: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Asia-Pacific: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: China: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: China: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Japan: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Japan: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: India: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: India: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: South Korea: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: South Korea: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Australia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Australia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Indonesia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Indonesia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Europe: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Europe: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Germany: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Germany: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: France: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: France: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: United Kingdom: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: United Kingdom: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Italy: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Italy: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Spain: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Spain: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Russia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Russia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Latin America: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Latin America: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Brazil: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Brazil: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Mexico: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Mexico: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Middle East and Africa: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Middle East and Africa: Rapid Acting Insulin Market: Breakup by Country (in %), 2022
  • Figure 72: Middle East and Africa: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Global: Rapid Acting Insulin Industry: SWOT Analysis
  • Figure 74: Global: Rapid Acting Insulin Industry: Value Chain Analysis
  • Figure 75: Global: Rapid Acting Insulin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Rapid Acting Insulin Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Rapid Acting Insulin Market Forecast: Breakup by Product (in Million US$), 2023-2028
  • Table 3: Global: Rapid Acting Insulin Market Forecast: Breakup by Indication (in Million US$), 2023-2028
  • Table 4: Global: Rapid Acting Insulin Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 5: Global: Rapid Acting Insulin Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Rapid Acting Insulin Market: Competitive Structure
  • Table 7: Global: Rapid Acting Insulin Market: Key Players
目次
Product Code: SR112023A4783

Abstract

The global rapid acting insulin market size reached US$ 7.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 9.7 Billion by 2028, exhibiting a growth rate (CAGR) of 4.61% during 2022-2028. The increasing risks of severity and mortality among patients, the growing focus on personalized medicine among the masses, and the increasing investments in research and development (R&D) activities are some of the major factors propelling the market.

A rapid-acting insulin is a type of insulin used in the treatment of diabetes, specifically for managing post-meal blood sugar spikes. It is designed to mimic the body's natural insulin response after eating, with an onset of action within 15 minutes of injection. This swift action helps to control blood sugar levels effectively, as it works to regulate the body's metabolism of glucose. Rapid-acting insulin peaks in its effect around one to two hours after administration, enabling it to efficiently lower high blood sugar levels during this critical period. It allows individuals with diabetes to time their injections in correlation with meal consumption, providing a more personalized treatment approach. It enhances diabetes management, providing patients with a better quality of life and reducing the risk of complications associated with uncontrolled blood sugar levels.

A rapid-acting insulin is a type of insulin used in the treatment of diabetes, specifically for managing post-meal blood sugar spikes. It is designed to mimic the body's natural insulin response after eating, with an onset of action within 15 minutes of injection. This swift action helps to control blood sugar levels effectively, as it works to regulate the body's metabolism of glucose. Rapid-acting insulin peaks in its effect around one to two hours after administration, enabling it to efficiently lower high blood sugar levels during this critical period. It allows individuals with diabetes to time their injections in correlation with meal consumption, providing a more personalized treatment approach. It enhances diabetes management, providing patients with a better quality of life and reducing the risk of complications associated with uncontrolled blood sugar levels.

Rapid Acting Insulin Market Trends/Drivers:

The Increasing Prevalence of Diabetes Among the Masses

The incidences of diabetes have been escalating at an alarming rate worldwide. Sedentary lifestyles, unhealthy dietary habits, and obesity are some of the key factors contributing to the rising incidence of diabetes. As more individuals are diagnosed with diabetes, the demand for effective and rapid-acting insulin continues to grow. Rapid-acting insulin plays a crucial role in managing post-meal blood sugar spikes, providing patients with a faster and more efficient way to control their glucose levels. Healthcare providers increasingly prescribe rapid-acting insulin to address the immediate insulin needs after meals, reducing the risk of hyperglycemia and associated complications. As the diabetic population expands, pharmaceutical companies are investing more in research and development to improve rapid-acting insulin formulations, enhancing their efficacy and convenience for patients.

Continual Technological Advancements

Innovations in medical technology have revolutionized insulin delivery systems, making them more user-friendly and accurate. Insulin pens, insulin pumps, and continuous glucose monitoring (CGM) devices have become increasingly popular among diabetes patients, facilitating easier administration and precise dosing of insulin. Rapid-acting insulin formulations are designed to work optimally with these modern delivery systems, further fueling their demand. Insulin pens offer discreet and convenient insulin delivery, while insulin pumps provide a continuous and personalized insulin infusion based on individual needs. These technological innovations have improved glycemic control, reduced the risk of hypoglycemic episodes, and enhanced patient's overall quality of life. As a result, the compatibility of rapid-acting insulin with these advanced devices has become a significant driving force behind the market's growth.

Increasing Awareness and Healthcare Infrastructure

Growing awareness about diabetes and its management, coupled with the expansion of healthcare infrastructure, has significantly contributed to the demand for rapid-acting insulin. Diabetes awareness campaigns, educational initiatives, and screening programs have led to early diagnosis and timely intervention for patients, increasing the number of individuals seeking appropriate treatment. Physicians and healthcare professionals are increasingly prescribing rapid-acting insulin to help patients achieve better post-prandial glucose control, preventing hyperglycemic episodes and long-term complications. Moreover, governments and healthcare organizations are investing in diabetes management programs, improving access to essential medications, including rapid-acting insulin. The combination of heightened awareness, better healthcare facilities, and increased affordability of diabetes treatment has created a favorable environment for the rapid-acting insulin market's expansion.

Rapid Acting Insulin Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global rapid acting insulin market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on product, indication and distribution channel.

Breakup by Product:

Lispro Insulin

Aspart Insulin

Glulisine Insulin

Lispro insulin dominates the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes lispro insulin, aspart insulin and glulisine insulin. According to the report, lispro insulin represented the largest segment.

Lispro insulin's popularity can be attributed to its fast onset of action, typically within a few minutes after administration, which helps control post-meal blood sugar spikes more effectively. This rapid action allows individuals with diabetes to time their insulin injections closer to meal consumption, providing greater flexibility and convenience in managing their blood glucose levels. Moreover, Lispro insulin is compatible with various insulin delivery devices, such as insulin pens and insulin pumps, further enhancing its ease of use and patient compliance. Apart from this, numerous physicians and healthcare providers frequently prescribe Lispro insulin due to its proven efficacy and safety profile. It has demonstrated its effectiveness in managing both type 1 and type 2 diabetes, making it a versatile option for a wide range of patients.

Breakup by Indication:

Type 1 Diabetes

Type 2 Diabetes

Type 2 diabetes hold the largest share in the market

A detailed breakup and analysis of the market based on the indication has also been provided in the report. This includes type 1 diabetes and type 2 diabetes. According to the report, type 2 diabetes accounted for the largest market share.

Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and impaired glucose regulation, leading to elevated blood sugar levels. Rapid-acting insulin plays a crucial role in the management of type 2 diabetes, particularly in addressing post-meal hyperglycemia. After a meal, individuals often experience a rapid increase in blood sugar levels, which can contribute to various health complications if left uncontrolled. As awareness about diabetes and its management continues to rise, coupled with the efforts to improve access to healthcare and diabetes care, the demand for rapid-acting insulin is expected to remain significant, solidifying its prominent position in the market. The increasing prevalence of type 2 diabetes, driven by factors like sedentary lifestyles, obesity, and an aging population, has resulted in a growing patient pool seeking diabetes management solutions.

Breakup by Distribution Channel:

Hospital Pharmacies

Drug Stores and Retail Pharmacies

Online Stores

Drug stores and retail pharmacies hold the largest share in the market

A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, drug stores and retail pharmacies and online stores. According to the report, drug stores and retail pharmacies accounted for the largest market share.

Drug stores and retail pharmacies are widespread and easily accessible, making them convenient points of purchase for patients seeking their diabetes medications. This accessibility ensures that patients can promptly refill their prescriptions and access essential rapid-acting insulin whenever needed, promoting better adherence to treatment regimens and overall diabetes management. Moreover, drug stores and retail pharmacies offer a diverse range of rapid-acting insulin products, providing patients with multiple options to choose from based on their specific needs and preferences. Pharmacists at these locations also play a vital role in patient education, helping individuals understand proper insulin administration, potential side effects, and the importance of medication adherence. Additionally, drug stores and retail pharmacies often participate in health insurance plans, which further facilitates access to rapid-acting insulin for patients, potentially reducing the financial burden associated with diabetes management.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest rapid acting insulin market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America boasts a high prevalence of diabetes, with both the United States and Canada experiencing an alarming increase in diabetes cases over the years. The region has a well-established healthcare infrastructure that emphasizes diabetes management and treatment. Access to advanced medical technologies, insulin delivery devices, and continuous glucose monitoring systems has enhanced patient care and contributed to the widespread adoption of rapid-acting insulin therapies. Moreover, North America is at the forefront of research and development in the pharmaceutical industry, leading to the introduction of innovative and effective rapid-acting insulin formulations. This continuous focus on advancements ensures that the region remains a key player in shaping the future of diabetes treatment. Furthermore, robust healthcare policies and insurance coverage in North America facilitate easier access to diabetes medications, including rapid-acting insulin, for a large portion of the population. This accessibility has significantly contributed to the region's dominant market share.

Competitive Landscape:

Pharmaceutical companies are investing heavily in R&D to discover and develop innovative rapid-acting insulin formulations. They aim to improve the pharmacokinetics, onset of action, and duration of these insulins to better meet the needs of patients. Additionally, companies are exploring new insulin delivery systems, such as ultra-rapid-acting insulins, oral insulin formulations, and inhalable insulin, to enhance convenience and patient compliance. Moreover, companies are pursuing regulatory approvals from health authorities in various countries to expand the market reach of their rapid-acting insulin products. Furthermore, leading players are focusing on expanding their presence in emerging economies with a high prevalence of diabetes. By increasing access to rapid-acting insulin in these regions, they can tap into untapped market potential and improve diabetes management globally. Additionally, pharmaceutical companies are actively involved in patient education and support programs to raise awareness about diabetes management and the importance of insulin therapy.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Adocia

Biocon Limited

Eli Lilly and Company

Gan & Lee Pharmaceuticals Co. Ltd.

Geropharm

MannKind Corporation

Merck & Co. Inc.

Novo Nordisk A/S,

Sanofi S.A.

Wockhardt Ltd.

Recent Developments:

In November 2022, Biocon Limited Completes Acquisition of Viatris' Global Biosimilars Business. The acquisition provides Biocon Biologics with direct commercial capabilities and supporting infrastructure in the advanced markets and several emerging markets, bringing it closer to patients, customers, and payors.

In July 2022, Merck & Co. Inc. announces its collaboration with Orion, Global Collaboration for the Development and Commercialization of ODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant prostate cancer.

In May 2022, MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device from Zealand Pharma. The acquisition of V-Go allows MannKind to expand its portfolio and strengthen its commitment to providing innovative mealtime diabetes solutions.

Key Questions Answered in This Report:

  • How has the global rapid acting insulin market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global rapid acting insulin market?
  • What is the impact of each driver, restraint, and opportunity on the global rapid acting insulin market?
  • What are the key regional markets?
  • Which countries represent the most attractive rapid acting insulin market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the rapid acting insulin market?
  • What is the breakup of the market based on the indication?
  • Which is the most attractive indication in the rapid acting insulin market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the rapid acting insulin market?
  • What is the competitive structure of the global rapid acting insulin market?
  • Who are the key players/companies in the global rapid acting insulin market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Rapid Acting Insulin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Lispro Insulin
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Aspart Insulin
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Glulisine Insulin
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Type 1 Diabetes
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Type 2 Diabetes
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Drug Stores and Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Adocia
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Biocon Limited
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Eli Lilly and Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Gan & Lee Pharmaceuticals Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Geropharm
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 MannKind Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Merck & Co. Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Novo Nordisk A/S
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Wockhardt Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials